BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit (NASDAQ:BCDA)March 25, 2026
Share Facebook Twitter LinkedIn Pinterest Email Stock index futures jump as U.S.-China agree to slash tariffs on temporary basis
BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit (NASDAQ:BCDA)March 25, 2026
Absci outlines $25B annual market potential for ABS-201 in AGA and advances endometriosis clinical program (NASDAQ:ABSI)March 25, 2026
By Press Room
By Press Room
By Press Room
